Zevra Therapeutics, Inc. (NASDAQ:ZVRA) CEO Neil F. Mcfarlane Sells 61,273 Shares of Stock

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) CEO Neil F. Mcfarlane sold 61,273 shares of the stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $7.86, for a total value of $481,605.78. Following the completion of the transaction, the chief executive officer now owns 222,060 shares in the company, valued at $1,745,391.60. This represents a 21.63 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Zevra Therapeutics Trading Up 1.0 %

Shares of ZVRA stock opened at $8.07 on Friday. Zevra Therapeutics, Inc. has a 12 month low of $4.20 and a 12 month high of $9.76. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84. The business’s 50 day moving average is $8.22 and its two-hundred day moving average is $8.04. The company has a market cap of $430.78 million, a PE ratio of -4.10 and a beta of 2.00.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.25). Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. The business had revenue of $3.70 million during the quarter, compared to the consensus estimate of $5.04 million. During the same period in the prior year, the company posted ($0.40) earnings per share. Equities analysts predict that Zevra Therapeutics, Inc. will post -1.95 EPS for the current year.

Analysts Set New Price Targets

ZVRA has been the topic of a number of research reports. HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of Zevra Therapeutics in a report on Wednesday, November 20th. Canaccord Genuity Group lowered their price target on Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating on the stock in a report on Thursday, November 14th. Finally, Cantor Fitzgerald upgraded Zevra Therapeutics to a “strong-buy” rating in a report on Wednesday, January 29th. Six research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Zevra Therapeutics has a consensus rating of “Buy” and a consensus target price of $21.57.

Institutional Investors Weigh In On Zevra Therapeutics

Hedge funds have recently modified their holdings of the business. Vestal Point Capital LP bought a new stake in shares of Zevra Therapeutics in the third quarter valued at approximately $3,644,000. Sanctuary Advisors LLC bought a new stake in shares of Zevra Therapeutics in the second quarter valued at approximately $474,000. Geode Capital Management LLC boosted its position in shares of Zevra Therapeutics by 14.2% in the third quarter. Geode Capital Management LLC now owns 1,043,864 shares of the company’s stock valued at $7,246,000 after acquiring an additional 129,600 shares during the period. Barclays PLC boosted its position in shares of Zevra Therapeutics by 292.6% in the third quarter. Barclays PLC now owns 57,599 shares of the company’s stock valued at $399,000 after acquiring an additional 42,926 shares during the period. Finally, Propel Bio Management LLC bought a new position in Zevra Therapeutics in the third quarter worth $1,248,000. 35.03% of the stock is owned by institutional investors.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.